Changes in the characteristics of the bone marrow during therapy for acute non-lymphocytic leukemia: Relationship to response to remission induction therapy

Harvey D. Preisler, Azra Raza, Nozar Azarnia, Irene Rakowsky, Maurice Barcos, George Browman, Lynda Booker, Jack Goldberg, Arlan Gottleib, James Brennan, Hans Grunwald, Kanti Rai, Kenneth Miller, Ralph Vogler, Lee Winton, Richard Larson

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

The bone marrows of patients with acute non-lymphocytic leukemia being treated with 'high dose' cytosine arabinoside remission induction therapy were sampled prior to the initiation of chemotherapy, after 6 days of therapy and again 7 days after the conclusion of therapy. These studies demonstrated that the marrows of patients who would enter remission (CR patients) contained less leukemic cells prior to therapy than patients who would fail to enter remission because of persistent leukemia (resistant disese, or RD patients). A comparison of the day 6 or 7-day post-therapy marrows with the pretherapy marrow demonstrated that while the % reduction in leukemic cells was greater for CR patients than for RD patients, the absolute reduction in leukemic cell mass was the same for both groups. While there was no relationship between the percentage of cells in S phase and the pretherapy leukemic cell mass, the greater the pretherapy leukemic cell mass the greater the likelihood that the leukemic cells would be resistant to the metabolic effects of cytosine arabinoside in vitro.

Original languageEnglish
Pages (from-to)563-571
Number of pages9
JournalEuropean Journal of Cancer and Clinical Oncology
Volume21
Issue number5
DOIs
StatePublished - May 1985
Externally publishedYes

Fingerprint

Dive into the research topics of 'Changes in the characteristics of the bone marrow during therapy for acute non-lymphocytic leukemia: Relationship to response to remission induction therapy'. Together they form a unique fingerprint.

Cite this